NanoVibronix (NanoVibronix) Short-Term Debt & Capital Lease Obligation : $0.01 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. NanoVibronix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.01 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. NanoVibronix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

NanoVibronix Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for NanoVibronix's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Short-Term Debt & Capital Lease Obligation Chart

NanoVibronix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.01

0.05

0.08

0.01

NanoVibronix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.08	0.06	0.04	0.02	0.01

NanoVibronix Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

NanoVibronix Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

NanoVibronix (NanoVibronix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

56R0:Germany

Address

525 Executive Boulevard, Elmsford, New York, NY, USA, 10523

Website

https://www.nanovibronix.com

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Executives

Christopher M Fashek	director	8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown	officer: Chief Financial Officer	18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson	director	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika	director	TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein	director	IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob	director, officer: Chief Medical Officer	HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein	director	C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris	director, officer: VP of Technology	105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly	10 percent owner	P.O. BOX 1443, BROOKLANDVILLE MD 21022